AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02045940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
Study NCT03932760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT Program
Description: UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
Study NCT03932760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
Study NCT00902460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam; CP-690,550 + midazolam
Description: Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
Study NCT00902460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + midazolam; midazolam
Description: Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
Study NCT00791752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending single doses (start dose 2 mg), oral suspension
Study NCT00791752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol
Description: Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
Study NCT01574651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
Study NCT00727792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI -Clinical
Description: MRI done is standard of care
Study NCT00727792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Research
Description: MRI includes extra sequences
Study NCT02774148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
Study NCT02774148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: The patient will receive 1,000mg po Acetaminophen every 8 hours.
Study NCT02134470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Description: Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
Study NCT01612130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg of Valeriana officinalis L
Description: A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
Study NCT01612130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 100mg
Description: A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
Study NCT02648568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis plus relaxation
Description: The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
Study NCT02648568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
Study NCT03058900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
Study NCT03058900 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Drug: Placebo (saline)
Description: One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
Study NCT03058900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Weekly methotrexate in maximum tolerable dosis
Study NCT03058900 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Weekly methotrexate in maximum tolerable dosis
Study NCT00788788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HELIOX
Description: HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
Study NCT01005095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
Study NCT01005095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
Study NCT00277784 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound examination
Description: one ultrasound examination
Study NCT02647424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole 2.5 mg daily from Day 2 to 6
Study NCT02647424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene
Description: After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
Study NCT01064791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 1) + tacrolimus + standard of care medications
Description: sotrastaurin (100mg bid) + tacrolimus + standard of care medications
Study NCT01064791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 2) + tacrolimus + standard of care medications
Description: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Study NCT01064791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (Dose 3) + tacrolimus + standard of care medications
Description: sotrastaurin (300mg bid) + tacrolimus + standard of care medications
Study NCT01064791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid + tacrolimus + standard of care medications
Description: mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
Study NCT00670800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
Study NCT04933487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
Study NCT01428531 — intervention group
Intervention type: DRUG
Intervention: Fondaparinux Sodium
Study NCT01411956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-minute video episode of patient education TV sitcom White Coats
Description: The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
Study NCT04244786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
Study NCT01411956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo video
Description: The control group watched a 25-minute patient education video on depression.
Study NCT01984918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder
Description: A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
Study NCT01984918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-SMS reminder
Description: No Stext message reminder via Short Message Service (SMS) will be sent
Study NCT04309708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine pump infusion
Description: Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
Study NCT04309708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimodipine pump infusion
Description: Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
Study NCT02045940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
Study NCT04244786 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
Study NCT04244786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention for participants who discontinued prior to randomization
Study NCT03657888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Club Denmark (FCD)
Description: Participation in Family Club Denmark
Study NCT03657888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: Participants on the waiting list
Study NCT01572038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Study NCT01572038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Study NCT01572038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Study NCT01572038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
Study NCT01572038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
Study NCT00489853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol Turbuhaler 320/9µg
Description: Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
Study NCT00489853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide/formoterol Turbuhaler 320/9µg
Description: Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
Study NCT00489853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol Turbuhaler 9µg
Description: Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
Study NCT00489853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: formoterol Turbuhaler 9µg
Description: Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
Study NCT00489853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 inhalation twice daily
Study NCT00489853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 inhalation twice daily
Study NCT00518908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 3.2 Vol % for postconditioning
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 5 mg
Description: One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 10 mg
Description: Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
Study NCT05342272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine taurine PVP gel
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study NCT05342272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Study NCT03239080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
Study NCT03239080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
Study NCT02699567 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 50 mg
Description: One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 20 mg
Description: One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
Study NCT01396811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33525
Description: Daily for 14 days
Study NCT01396811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14 days
Study NCT04058860 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS monitoring
Description: Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
Study NCT04058860 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cox monitoring
Description: Cerebral autoregulation monitoring
Study NCT04058860 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sublingual microscopy
Description: Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
Study NCT02603809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
Study NCT01012336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant/Ramosetron/Dexamethasone
Description: Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg.
Study NCT02953990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMS Program
Study NCT02397330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Study NCT00246701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin
Study NCT02397330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Study NCT02397330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: ultrasound guided nerve blocks
Study NCT02397330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound guided nerve blocks
Study NCT02397330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Study NCT02397330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Study NCT04342104 — intervention group
Intervention type: OTHER
Intervention: Monitoring for aggravation
Description: Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP